Halozyme Therapeutics (HALO) Stock Overview
A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HALO Community Fair Values
Create NarrativeSee what 92 others think this stock is worth. Follow their fair value or set your own to get alerts.
Halozyme Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$66.47 |
| 52 Week High | US$79.50 |
| 52 Week Low | US$42.01 |
| Beta | 1.16 |
| 1 Month Change | -14.57% |
| 3 Month Change | 13.51% |
| 1 Year Change | 28.94% |
| 3 Year Change | 41.67% |
| 5 Year Change | 123.13% |
| Change since IPO | 1,501.69% |
Recent News & Updates
Recent updates
Halozyme: Royalty Harvest Now, Post-2027 Roadmap Still Thin
Sep 30Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Rockets 27% But Many Are Still Ignoring The Company
Aug 21
Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 08Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Apr 20Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?
Mar 29Halozyme Therapeutics: Steady Growth In A Challenged Market
Mar 14Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 21Halozyme Therapeutics, Inc. (NASDAQ:HALO) Might Not Be As Mispriced As It Looks
Jan 28Halozyme: Recent Approvals Alter My Appetite
Dec 31Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly
Nov 28Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Nov 20Halozyme: Looking For More Growth Following Record Q3 Earnings
Nov 05Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet
Oct 29Halozyme Therapeutics: Behind The Pullback
Oct 22
Extended Patent Protections And New Approvals Propel Revenue And Earnings Growth
Expanded patent coverage and new ENHANZE approvals open new market segments and extend royalty income, improving revenue and net margins.Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Aug 14Halozyme Therapeutics: The Story Brightens
Jun 07Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Shareholder Returns
| HALO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.3% | 3.5% | 1.2% |
| 1Y | 28.9% | 3.1% | 16.3% |
Return vs Industry: HALO exceeded the US Biotechs industry which returned 3.1% over the past year.
Return vs Market: HALO exceeded the US Market which returned 16.3% over the past year.
Price Volatility
| HALO volatility | |
|---|---|
| HALO Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HALO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HALO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 350 | Helen Torley | halozyme.com |
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
Halozyme Therapeutics, Inc. Fundamentals Summary
| HALO fundamental statistics | |
|---|---|
| Market cap | US$7.77b |
| Earnings (TTM) | US$557.28m |
| Revenue (TTM) | US$1.18b |
Is HALO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HALO income statement (TTM) | |
|---|---|
| Revenue | US$1.18b |
| Cost of Revenue | US$265.29m |
| Gross Profit | US$913.38m |
| Other Expenses | US$356.10m |
| Earnings | US$557.28m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.76 |
| Gross Margin | 77.49% |
| Net Profit Margin | 47.28% |
| Debt/Equity Ratio | 453.5% |
How did HALO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/21 12:38 |
| End of Day Share Price | 2025/10/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Halozyme Therapeutics, Inc. is covered by 29 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | Barclays |
| Robert Wasserman | Benchmark Company |
| Clarence Powell | BMO Capital Markets Equity Research |